{
    "clinical_study": {
        "@rank": "148102", 
        "arm_group": [
            {
                "arm_group_label": "Part 1: LFX453/placebo", 
                "arm_group_type": "Experimental", 
                "description": "once daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2"
            }, 
            {
                "arm_group_label": "Part 2 groupA: LFX453/placebo", 
                "arm_group_type": "Experimental", 
                "description": "once daily: LFX453 cream 1 / Placebo 1"
            }, 
            {
                "arm_group_label": "Part 2 groupB: LFX453/placebo", 
                "arm_group_type": "Experimental", 
                "description": "once daily: LFX453 cream 2 / Placebo 2"
            }, 
            {
                "arm_group_label": "Part 2 groupC: LFX453/LFX453", 
                "arm_group_type": "Experimental", 
                "description": "once daily: LFX453 cream 1 / LFX453 cream 2"
            }, 
            {
                "arm_group_label": "Part 2 groupD: Imiquimod", 
                "arm_group_type": "Other", 
                "description": "once daily: imiquimod cream"
            }, 
            {
                "arm_group_label": "Part 3: LFX453/placebo", 
                "arm_group_type": "Experimental", 
                "description": "twice daily: LFX453 cream 1 high dose / LFX453 cream 1 low dose /Placebo 1 / LFX453 cream 2 high dose / LFX453 cream 2 low dose / Placebo 2"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this first-in human study is to demonstrate systemic and local tolerability\n      and investigate pharmacokinetics of LFX453 after multiple topical applications in healthy\n      subjects.\n\n      The current study has been designed with three distinct parts. Part 1 focuses on safety and\n      tolerability of once daily application on the back, prior to moving forward and assessing\n      the safety and tolerability in more sensitive treatment areas in Part 2 or twice daily\n      application in Part 3."
        }, 
        "brief_title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female subjects of non-childbearing potential, 18 to 65 years of age\n             inclusive (at the time of the screening visit), and in good health as determined by\n             past medical history, physical examination, vital signs, electrocardiogram, and\n             laboratory tests at screening.\n\n          -  Male subjects must agree to total abstinence from male:female intercourse or agree to\n             use a condom during drug dosing and for four weeks after dosing has stopped.\n\n        Exclusion Criteria:\n\n          -  History of serious allergic reaction to any drug.\n\n          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical\n             classes.\n\n          -  History of any atopic dermatitis (only within the last 2 years), autoimmune disease,\n             psoriasis or erythema multiforme.\n\n          -  Presence of skin disease (e.g. warts) or skin features on treatment areas that may\n             affect local tolerability or the ability of the investigator to evaluate local\n             tolerability.\n\n          -  History of heart failure, left ventricular dysfunction or known family history or\n             known presence of long QT syndrome.\n\n          -  A history of clinically significant ECG abnormalities, or any of the following ECG\n             abnormalities at screening or baseline:\n\n               -  2nd or 3rd degree AV-block\n\n               -  PR > 200 msec\n\n               -  QRS complex > 120 msec\n\n               -  QTcF > 450 msec (males)\n\n               -  QTcF > 460 msec (females)\n\n          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a\n             female after conception and until the termination of gestation, confirmed by a\n             positive hCG laboratory test.\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052687", 
            "org_study_id": "CLFX453X2101", 
            "secondary_id": "2013-002344-84"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part 1: LFX453/placebo", 
                    "Part 2 groupA: LFX453/placebo", 
                    "Part 2 groupB: LFX453/placebo", 
                    "Part 2 groupC: LFX453/LFX453", 
                    "Part 3: LFX453/placebo"
                ], 
                "description": "LFX453 high dose cream 1", 
                "intervention_name": "LFX453 H1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: LFX453/placebo", 
                    "Part 2 groupA: LFX453/placebo", 
                    "Part 2 groupB: LFX453/placebo", 
                    "Part 2 groupC: LFX453/LFX453", 
                    "Part 3: LFX453/placebo"
                ], 
                "description": "LFX453 low dose cream 1", 
                "intervention_name": "LFX453 L1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: LFX453/placebo", 
                    "Part 2 groupA: LFX453/placebo", 
                    "Part 2 groupB: LFX453/placebo", 
                    "Part 2 groupC: LFX453/LFX453", 
                    "Part 3: LFX453/placebo"
                ], 
                "description": "LFX453 high dose cream 2", 
                "intervention_name": "LFX453 H2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: LFX453/placebo", 
                    "Part 2 groupA: LFX453/placebo", 
                    "Part 2 groupB: LFX453/placebo", 
                    "Part 2 groupC: LFX453/LFX453", 
                    "Part 3: LFX453/placebo"
                ], 
                "description": "LFX453 low dose cream 2", 
                "intervention_name": "LFX453 L2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Part 2 groupD: Imiquimod", 
                "description": "Imiquimod cream", 
                "intervention_name": "Imiquimod", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: LFX453/placebo", 
                    "Part 2 groupA: LFX453/placebo", 
                    "Part 2 groupB: LFX453/placebo", 
                    "Part 3: LFX453/placebo"
                ], 
                "description": "Placebo cream 1", 
                "intervention_name": "Placebo 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part 1: LFX453/placebo", 
                    "Part 2 groupA: LFX453/placebo", 
                    "Part 2 groupB: LFX453/placebo", 
                    "Part 3: LFX453/placebo"
                ], 
                "description": "Placebo cream 2", 
                "intervention_name": "Placebo 2", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Imiquimod"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Healthy volunteer", 
        "lastchanged_date": "January 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Mid Glamorgan", 
                    "country": "United Kingdom", 
                    "zip": "CF484DR"
                }, 
                "name": "Novartis Investigative Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "6", 
        "official_title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453 After Multiple Topical Applications in Healthy Volunteers", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Summarized statistics on adverse events will be reported under categories such as total adverse events, serious adverse events and death.", 
                "measure": "General safety (number of subjects with adverse events)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }, 
            {
                "description": "Summarized statistics on 5-point scale tolerability scores over 14 days of treatment.", 
                "measure": "Local skin tolerability (tolerability score)", 
                "safety_issue": "Yes", 
                "time_frame": "14 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052687"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate systemic steady state pharmacokinetics in human after topical administration of LFX453.", 
                "measure": "All parts: Amount (ng/mL) of LFX453 in plasma", 
                "safety_issue": "No", 
                "time_frame": "14 days"
            }, 
            {
                "description": "LFX453 analyzed in skin.", 
                "measure": "Part 1 and 2: LFX453 concentrations (ng/g) in the skin", 
                "safety_issue": "No", 
                "time_frame": "Day 14 and between days 18-21"
            }, 
            {
                "description": "LFX453 analyzed in urine.", 
                "measure": "All parts: LFX453 concentration (ng/mL) in urine", 
                "safety_issue": "No", 
                "time_frame": "Day 14"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}